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Discovering the genetic basis of aMendelian phenotype establishes a causal link between genotype and phenotype, making possible car-
rier and population screening and direct diagnosis. Such discoveries also contribute to our knowledge of gene function, gene regulation,
development, and biologicalmechanisms that can be used for developing new therapeutics. As of February 2015, 2,937 genes underlying
4,163Mendelian phenotypes have been discovered, but the genes underlying ~50% (i.e., 3,152) of all knownMendelian phenotypes are
still unknown, and many more Mendelian conditions have yet to be recognized. This is a formidable gap in biomedical knowledge.
Accordingly, in December 2011, the NIH established the Centers for Mendelian Genomics (CMGs) to provide the collaborative frame-
work and infrastructure necessary for undertaking large-scale whole-exome sequencing and discovery of the genetic variants responsible
for Mendelian phenotypes. In partnership with 529 investigators from 261 institutions in 36 countries, the CMGs assessed 18,863 sam-
ples from 8,838 families representing 579 known and 470 novel Mendelian phenotypes as of January 2015. This collaborative effort has
identified 956 genes, including 375 not previously associated with human health, that underlie a Mendelian phenotype. These results
provide insight into study design and analytical strategies, identify novel mechanisms of disease, and reveal the extensive clinical vari-
ability of Mendelian phenotypes. Discovering the gene underlying every Mendelian phenotype will require tackling challenges such as
worldwide ascertainment and phenotypic characterization of families affected by Mendelian conditions, improvement in sequencing
and analytical techniques, and pervasive sharing of phenotypic and genomic data among researchers, clinicians, and families.Introduction
Improved understanding of human disease was a primary
goal of the Human Genome Project (HGP).1 This promise
has, in part, been realized with the identification of the
consequence of germline mutation (single-nucleotide var-
iants [SNVs] and copy-number variants [CNVs]) for more
than 2,900 protein-coding genes in humans.2–4 These dis-
ease-associated mutations directly link DNA variants to
altered protein function or dosage and to human pheno-
types, thus transforming our understanding of the basic
biology of development and physiological homeostasis
in health and disease. Indeed, much of what is known
about the relationship between gene function and human
phenotypes is based on the study of rare variants underly-
ing Mendelian phenotypes. Furthermore, these discoveries
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The Amerpeutic strategies for a growing number of rare and com-
mon diseases.5–8
Much remains to be learned. The HGP and subsequent
annotation efforts have established that there are
~19,000 predicted protein-coding genes in humans.9,10
Nearly all are conserved across the vertebrate lineage
and are highly conserved since the origin of mammals
~150–200 million years ago,11–13 suggesting that certain
mutations in every non-redundant gene will have pheno-
typic consequences, either constitutively or in response
to specific environmental challenges. The continuing
pace of discovery of new Mendelian phenotypes and
the variants and genes underlying them supports this
contention.
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Mendelian phenotypes identified thus far result from
altered function, localization, or presence of the encoded
proteins. Furthermore, few Mendelian phenotypes appear
to be caused exclusively by mutations outside coding re-
gions.14 This is not only a matter of ascertainment bias,
given that loci that are well mapped by unbiased analysis
of linkage data prior to the discovery of underlying causes
have yielded extremely high ratios in favor of variants that
alter protein function.15 However, progress in the elucida-
tion of promoters and tissue-specific regulatory elements
by projects such as ENCODE16 and in linking perturba-
tions in these elements to alterations of gene expression
holds promise for the identification of new Mendelian
phenotypes caused by non-coding mutations.17 Mende-
lian phenotypes for which mutations have not been
discovered in coding regions or canonical splice sites are
ideal candidates for such studies.
Our increasingly sophisticated ability to phenotype hu-
mans, coupled with differences in physiology between hu-
mans and model organisms, argues that primary mutation
discovery in humans will remain crucial to progress.18
Moreover, now that a finite set of protein-coding genes
has been defined, determining the phenotypic conse-
quences of their variation represents a vital and attainable
goal partly because of the advances in the production
and analysis of whole-exome sequencing (WES) and
whole-genome sequencing (WGS) data.19–24 Each success-
ful discovery will define potential diagnostic, preventive,
and therapeutic opportunities for the corresponding
diseases and illuminate normal biology and disease
mechanisms.25,26
The Burden of Mendelian Disease
In aggregate, clinically recognized Mendelian phenotypes
compose a substantial fraction (~0.4% of live births) of
known human diseases, and if all congenital anomalies
are included, ~8% of live births have a genetic disorder
recognizable by early adulthood.27 This translates to
approximately eight million children born worldwide
each year with a ‘‘serious’’ genetic condition, defined as a
condition that is life threatening or has the potential to
result in disability.28 In the US alone, Mendelian disorders
collectively affect more than 25 million people and are
associated with high morbidity, mortality, and economic
burden in both pediatric and adult populations.28,29 Birth
defects, of which Mendelian phenotypes compose an
unknown but most likely substantial proportion, are the
most common cause of death in the first year of life, and
each year, more than three million children under the
age of 5 years die from a birth defect, and a similar number
survive with substantial morbidity. Beyond the emotional
burden, each child with a genetic disorder has been esti-
mated to cost the healthcare system a total of $5,000,000
during their lifetime.28,29
It remains a challenge to diagnosemanyMendelian phe-
notypes by phenotypic features and conventional diag-
nostic testing. In a general clinical genetics setting, the200 The American Journal of Human Genetics 97, 199–215, August 6diagnostic rate is ~50%.30 Across a broader range of rare
diseases, diagnostic rates are even lower. For example, in
the NIH Undiagnosed Disease Program, the diagnostic
rate was, despite state-of-the-art evaluations, 34% in adults
and 11% in children.31 Moreover, the time to diagnosis is
often prolonged (the ‘‘diagnostic odyssey’’); in a European
survey of the time to diagnosis of eight rare diseases,
including cystic fibrosis (MIM: 602421) and fragile X syn-
drome (MIM: 309550), 25% of families waited between
5 and 30 years for a diagnosis, and the initial diagnosis
was incorrect in 40% of these families.32
Molecular diagnostic rates for many Mendelian pheno-
types are similarly low. For example, of 292 well-character-
ized categories of Mendelian phenotypes for which clinical
testing is available (GeneReviews, July 2014; Table S1), a
causal variant can be identified in only 52% of cases overall
(Figure 1A). Diagnostic rates vary widely by phenotype and
are inversely correlated with the level of genetic heteroge-
neity (Spearman correlation r ¼ 0.155, p value ¼
0.008019; Figure 1B; Table S2). These observations are
consistent with diagnostic rates of 25%–75% for many
major categories of inherited conditions (e.g., kidney dis-
ease,33 cardiomyopathy,34 epilepsy,35 etc.) The increasing
availability of clinical WES testing holds promise for
improving diagnostic yield, and although the diagnostic
rate reported with this technology is currently only
~25%–30%, it represents a substantially higher rate than
the diagnostic yield of other genomic assays, such as
karyotyping (<5%) and array comparative genomic hy-
bridization (~15%–20%).36,37 Importantly, studies of the
diagnostic efficacy of clinical WES show that a substantial
fraction (25%–30%) of the diagnostic successes depends
on recent progress in the discovery of genes underlying
disease.36,38 This observation highlights the value of
continued research into the genetic basis of Mendelian
phenotypes. Moreover, it predicts that diagnostic rates
will continue to increase as we work toward a more com-
plete catalog of the genes and variants responsible for
human disease.
The Scope of Mendelian-Disease-Related Phenotypes
Our knowledge of the diversity of Mendelian pheno-
types is increasingly sophisticated, but substantial gaps
remain.39 Specifically, it is challenging to establish the
number of Mendelian phenotypes that exist, to delineate
new Mendelian phenotypes, to distinguish novel from
known Mendelian phenotypes, to define what constitutes
expansion of a known phenotype, and to develop metrics
for assessing the relationships and diversity of phenotypes
caused by variants in the same gene. These gaps are due, in
part, to the diversity of ‘‘normal’’ human morphology
and physiology, the challenge of defining normal versus
abnormal, and the difficulty of setting limits for traits
with quantitative distributions.40,41 Moreover, biological
variation is, in large part, not binary but rather described
by partially overlapping distributions.42–45 With these
caveats in mind, we analyzed OMIM entries (February, 2015
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Figure 1. Clinical Diagnostic Rates of
Mendelian Conditions for which Gene(s)
Have Been Identified
All Mendelian conditions, or phenotypic
series, included are listed in GeneReviews
and might be genetically heterogeneous
(i.e., caused by mutations in one or more
genes).
(A) Histogram of the percentage of individ-
uals who had a Mendelian condition
(x axis) and who received a corresponding
molecular diagnosis from clinical testing.
Collectively, for 292 Mendelian condi-
tions, a causal variant could be identified
in only ~52% of affected subjects overall.
(B) Boxplots show the molecular diag-
nostic rate (y axis) for Mendelian condi-
tions organized by the number of causal
genes (x axis). The diagnostic rate per con-
dition is inversely correlated with the level
of genetic heterogeneity (Spearman corre-
lation r ¼ 0.155, p value ¼ 0.008019).2015) to identify 7,440 rare Mendelian phenotypes (7,315
monogenic; 125 chromosomal duplications and/or dele-
tions). This number is not static; ~300 newMendelian phe-
notypes are added to OMIM each year, and this probably
underestimates the number of phenotypes newly recog-
nized each year. Delineation of new Mendelian pheno-
types in populations worldwide is limited by a lack
of infrastructure, resources, and expertise46,47 Moreover,
studies of model organisms show that the number and
types of recognized phenotypes increase with expanding
environmental challenges.48 Therefore, to completely
enumerate ‘‘all’’ human Mendelian phenotypes, it will be
necessary to consider a more comprehensive span of envi-
ronmental conditions and develop more-sophisticated
tools to evaluate phenotype.49
Studies in mice with engineered loss-of-function (LOF)
mutations suggest that the majority of the gene knock-
outs compatible with survival to birth are associated
with a recognizable phenotype, whereas ~30% of gene
knockouts lead to in utero or perinatal lethality.50 Of
the latter, it remains to be determined whether partial
LOF mutations (i.e., hypomorphic alleles) or other classes
of mutations (e.g., gain of function, dosage differences
due to gene amplification,51 etc.) in the same genes might
result in viable phenotypes. Nevertheless, given the high
degree of evolutionary conservation between humans
and mice, mutations in the majority of non-redundant
human protein-coding genes are likely to result in Mende-
lian phenotypes, most of which remain to be character-
ized (Figure 2).The American Journal of Human GRelationship between Mendelian
Disease Traits and Common
Disease
The etiologies of common diseases,
such as hypertension, coronary artery
disease, diabetes, obesity, scoliosis,and autism, are heterogeneous and typically include a
small subset of individuals with a monogenic condition
underlying their diagnosis with a common disease.52–55
The variants responsible for this small fraction of affected
individuals rarely explain much of the genetic contribu-
tion to these common diseases,56,57 but they are neverthe-
less often highly relevant to our understanding of more-
general mechanisms of these conditions.53 A classic
example in cardiovascular disease research is the identifica-
tion of the genetic basis of rare, monogenic forms of hyper-
cholesterolemia, which provided critical insights into the
relevance of lipid transport.58 In turn, these findings
have led to the development of new therapies for com-
mon, complex cardiovascular diseases by targeting the
implicated genes and pathways.53 Collectively, nearly
20% of genes implicated in Mendelian phenotypes also
either contain or are nearest to a variant responsible
for a genome-wide association study (GWAS) signal
that achieves genome-wide significance for a complex
trait (Figure 3A; Supplemental Material and Methods;
Figure S1). In contrast, ~15% of all genes overall underlie
a Mendelian phenotype, suggesting that genes implicated
in Mendelian phenotypes are enriched in GWAS signals.
The fraction of genes that are found near GWAS signals
and in which variants are responsible for Mendelian phe-
notypes is also positively correlated with the strength of
association (Figure 3B). Widespread co-morbidity among
Mendelian phenotypes and complex diseases provides
further evidence that variation in genes that underlie Men-
delian phenotypes plays a role in complex disease.59enetics 97, 199–215, August 6, 2015 201
 c
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Figure 2. Relationship between Human
Protein-Coding Genes and Mendelian
Phenotypes
Of approximately ~19,000 protein-coding
genes predicted to exist in the human
genome, variants that cause Mendelian
phenotypes have been identified in
~2,937 (~15.5%; orange squares). Genes
underlying ~643 Mendelian phenotypes
(~3.38%; gray squares) have been mapped
but not yet identified. On the basis of anal-
ysis of knockout mouse models, LOF vari-
ants in up to ~30% of genes (~5,960; red
squares) could result in embryonic lethality in humans. Note that the consequences of missense variants in these genes could be
different. For a minimum of ~52% of genes (~10,330; blue squares), the impact in humans has not yet been determined. Collectively,
~16,063 genes remain candidates for Mendelian phenotypes.Development of new therapeutics to address common
diseases that constitute major public-health problems is
limited by the ignorance regarding the fundamental
biology underlying disease pathogenesis.60 As a conse-
quence, 90% of drugs entering human clinical trials fail,
commonly because of a lack of efficacy and/or unantici-
pated mechanism-based adverse effects.61 Studies of fam-
ilies affected by rare Mendelian phenotypes segregating
with large-effect mutations that increase or decrease risk
for common disease can directly establish the causal rela-
tionship between genes and pathways and common dis-
eases and identify targets likely to have large beneficial
effects and fewer mechanism-based adverse effects when
manipulated. For example, certain Mendelian forms of
high and low blood pressure are due to mutations that
cause increases and decreases, respectively, in renal salt
reabsorption and net salt balance; these discoveries identi-
fied promising new therapeutic targets, such as KCNJ1 (po-
tassium channel, inwardly rectifying, subfamily J, member
1 [MIM: 600359]), for which drugs are now in clinical tri-
als. Understanding the role of salt balance in blood pres-
sure has provided the scientific basis for public-health
efforts in more than 30 countries to reduce heart attacks,
strokes, and mortality by modest reduction in dietary salt
intake.62 Similarly, understanding the physiological effects
of CFTR (cystic fibrosis transmembrane conductance regu-
lator [MIM: 602421]) mutations responsible for cystic
fibrosis has led to allele-specific therapies that significantly
improve pulmonary function in affected individuals.63
Other common-disease drugs based on gene discoveries
for Mendelian phenotypes (e.g., orexin antagonists for
sleep,64 beta-site APP-cleaving enzyme 1 [BACE1] inhibi-
tors for Alzheimer dementia,65 proprotein convertase, sub-
tilisin/kexin type 9 [PCSK9] monoclonal antibodies to
lower low-density lipoprotein levels66) are undergoing
advanced clinical trials. Discoveries such as these
will directly facilitate the goals of the Precision Medicine
Initiative.67
Use of other approaches, such as identification of com-
mon variants of small effect, might be less effective at facil-
itating drug development. For example, of 348 proteins
specifically targeted by current therapeutics, 42.5% are en-
coded by a gene responsible for a Mendelian phenotype,202 The American Journal of Human Genetics 97, 199–215, August 6whereas only 28.2% of proteins targeted by current thera-
peutics are encoded by a gene found within GWAS signals
(the closest downstream and upstream genes were counted
per intergenic signal, and all overlapping genes were
counted per coding signal). Accounting for the over-repre-
sentation of genes underlying Mendelian phenotypes in
GWAS signals, 27.3% of proteins targeted are only encoded
by a gene underlying a Mendelian phenotype, whereas
13.6% of proteins targeted are found only in a GWAS
signal. Moreover, compared to therapeutics that are still
in clinical trials, currently approved therapeutics are en-
riched with drugs that target a protein encoded by a gene
in which mutations are responsible for a Mendelian
phenotype (32.8% versus 42.5%), suggesting that drugs
associated with a gene underlying a Mendelian phenotype
more often receive FDA approval. No such relationship is
observed for genes found within GWAS signals (28.2%
are FDA approved, whereas 29.4% are in clinical trials).
Accordingly, using information about whether a target
protein is encoded by a gene underlying a Mendelian
phenotype might help to stratify drug candidates for
development.
Gene-Discovery Efforts for Mendelian Phenotypes to
Date
The first successful efforts to identify genes underlying
Mendelian phenotypes often required extensive prior
knowledge of disease biology, including the identity of
the affected protein. In 1986, discovery of mutations
causing chronic granulomatous disease in CYBB (MIM:
300481) demonstrated that mapping followed by
sequencing of genes within the maximum-likelihood in-
terval offered a promising alternative for discovering genes
underlying disease, and during the next 10 years, 42 genes
associated with Mendelian phenotypes were identified via
positional cloning.68 The ensuing two decades witnessed a
steady accumulation of genes discovered to underlie
Mendelian phenotypes by a combination of positional
cloning and candidate-gene approaches. However, it
became increasingly obvious that gene identification
for most Mendelian phenotypes without a known cause
was difficult via these approaches. Gene-discovery strate-
gies based on WES and WGS introduced powerful, 2015
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Signals and Genes Underlying Mendelian
Phenotypes
(A) Plot of the fraction of GWAS-signal
genes that are also implicated in Mende-
lian phenotypes (MPs). Each orange dot
represents the proportion of GWAS signals
that, in a sliding window of 500 GWAS
signals, are mapped to a gene also known
to underlie a Mendelian condition. In
GWAS signals, approximately 26.6% of
genes with the top 500 lowest p values un-
derlie a Mendelian phenotype. In contrast,
only 14.2% of genes overall are known to
underlie a Mendelian phenotype, suggest-
ing that GWAS signals are more likely to
be enriched with genes implicated in Mendelian phenotypes. Varied colored dots represent the percentage of genes underlying a
Mendelian phenotype in GWAS signals underlying different phenotypic categories as follows (of increasing percentages from bottom
to top): 10% for reproductive traits (blue); 11% for respiratory traits (gold); 13% for autoimmune inflammatory traits (dark green);
16% for immunologic traits (blue); 17% for mental-health traits (teal); 19% for infectious-disease traits (gray); 21% for anthropometric
traits (brown); 23% for cancer (red); 25% for cardiovascular traits (tan); 26% for metabolomics traits (yellow); 28% for pharmacogenetic
traits (green); and 33% for musculoskeletal traits (blue).
(B) Cumulative plot of the proportion of GWAS signals in which a gene underlying a Mendelian phenotype (MP) was found (orange
dots) and GWAS signals in which a gene underlying a Mendelian phenotype was not found (gray dots). At virtually every p value, a
higher proportion of GWAS signals overlapped genes underlying Mendelian phenotypes.alternatives that were agnostic to both known biology and
mapping data.19,22,23,69–72 Combined with conventional
genetic approaches, WES and WGS have proved to be
disruptive technologies that have rapidly accelerated the
pace of discovery of genes underlying Mendelian pheno-
types, such that the pace of gene discovery has increased
from an average of ~166 per year between 2005 and 2009
to 236 per year between 2010 and 2014. Between January
of 2010 and February 2015, ~555 and ~613 genes
associated with monogenic Mendelian phenotypes were
discovered via next-generation sequencing approaches
and conventional approaches, respectively. However,
over this time period, there has been a rapid shift toward
increasing the use of WES and WGS, and since 2013,
WES and WGS have made almost three times as many dis-
coveries as conventional methods (Figure 4; Supplemental
Material and Methods; Figure S2).
Although substantial progress has been made toward
identifying the genetic basis of Mendelian phenotypes,
the genes underlying about half of all known Mendelian
phenotypes (i.e., 3,152) have not yet been discovered,
despite the fact that ~20% (i.e., 643) have been mapped
(~80% with robust linkage data [e.g., significant linkage
to a single region or recurrent structural variants (SVs)
involving the same region] according to a manual review)
as per data from OMIM (February 2015). Most of these
‘‘unsolved’’ Mendelian phenotypes are rare and often
have high locus heterogeneity and/or are intractable to
mapping-based approaches because they are caused by de
novo mutations in the germline or mosaicism in somatic
tissues.73–75 Sequencing technologies and analytical ap-
proaches have now sufficiently matured to make gene dis-
covery at scale for all Mendelian phenotypes feasible and
cost effective. To this end, national and international ef-
forts led by the human genetics community have emergedThe Amerto identify the genetic basis of Mendelian phenotypes at
scale even as the number of recognized phenotypes con-
tinues to increase each year.76–78
The Centers for Mendelian Genomics
Widespread, convenient, and cost-effective application of
WES and WGS for finding genes underlying Mendelian
phenotypes posed a number of challenges when the strat-
egy was first introduced.79 Moreover, achieving the goal
of finding all genes underlying all Mendelian phenotypes
requires searching the entire human population and there-
fore necessitates a worldwide collaboration among clini-
cians and scientists to identify and characterize both novel
andwell-knownMendelian phenotypes. Accordingly,mul-
tiple national efforts were initiated to establish the collabo-
rative framework and physical infrastructure necessary for
undertaking large-scale identification of affected individ-
uals, genomic sequencing, and gene discovery for Mende-
lian phenotypes; these included the NHGRI- and NHLBI-
supported Centers for Mendelian Genomics (CMGs),77
Finding of Rare Disease Genes (FORGE) Canada,76 and the
Wellcome Trust Deciphering Developmental Disabilities
(WTDDD),78 each of which was established in 2011. The
CMGs consist of three centers: (1) the University of Wash-
ington Center for Mendelian Genomics, (2) the Baylor-
Hopkins Center for Mendelian Genomics, and (3) the Yale
Center for Mendelian Genomics. All of these consortia, as
well as a myriad of individual investigators and small
research groups, have made major contributions to gene
discovery for Mendelian phenotypes over the past 4 years.
The CMGs were expected to make substantial progress
toward discovering the genomic basis of most, if not all,
known Mendelian phenotypes. Specifically, the CMGs
had the following goals: (1) assess the genetic basis of
~1,000 Mendelian phenotypes in collaboration withican Journal of Human Genetics 97, 199–215, August 6, 2015 203
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Figure 4. Approximate Number of Gene
Discoveries Made byWES andWGS versus
Conventional Approaches since 2010
Since the introduction ofWES andWGS in
2010, the pace of discovery of genes impli-
cated in Mendelian phenotypes per year
has increased substantially, and the pro-
portion of discoveries made by WES or
WGS (blue) versus conventional ap-
proaches (red) has steadily increased (see
Supplemental Material and Methods for a
detailed description of the analysis). Since
2013, WES and WGS have discovered
nearly three times as many genes as con-
ventional approaches.investigators worldwide; (2) develop new methods and ap-
proaches for discovering the genetic basis of Mendelian
phenotypes; (3) generate public resources that can be lever-
aged by the biomedical community to facilitate investi-
gator-initiated gene-discovery efforts, studies of gene func-
tion, and clinical translation and interpretation of human
genome variation; and (4) lead and coordinate US efforts
with other large-scale projects aimed at discovering genes
implicated in Mendelian phenotypes. Key to accomplish-
ing these goals was that collaborating clinicians and inves-
tigators were able to access WES, WGS, and technical
expertise from the CMGs at no cost and preserve their con-
trol over data sharing, analysis, and rights to publish. It
was also anticipated that the overall genetic architecture
of Mendelian phenotypes would be further elucidated
and that novel underlying genetic mechanisms might be
revealed.
CMG Discoveries
As of January 2015, 18,863 samples representing 579
known and 470 novel Mendelian phenotypes from 8,838
families (see the CMG investigated phenotypes in the
Web Resources) have been assessed by the CMGs in part-
nership with 529 investigators from 261 institutions in
36 countries (i.e., ~1 of every 5 countries in the world)
(Figure 5). 60% of countries, 32% of institutions, and
20% of investigators are located outside of North America,
Europe, or Australia (Figure 6). Exome and whole-genome
data have been produced for 16,226 and 96 samples,
respectively, and about half of these sequences can be
deposited in dbGaP (Figure 5). Additionally, data for newly
identified causal variants have been made available
through ClinVar and via a new track on the UCSCGenome
Browser. Finally, web-based tools developed by the
CMGs, such as GeneMatcher and Geno2MP, provide a
mechanism for investigators with a candidate gene for a
Mendelian phenotype to connect with other clinicians
and/or basic scientists around the world with an interest
in the same gene and to link phenotypic profiles to rare
variants, respectively.80 Accordingly, the CMGs have em-
powered the entire international rare-disease research
community.204 The American Journal of Human Genetics 97, 199–215, August 6To assess progress toward identifying the genes underly-
ing Mendelian phenotypes, it is critical to apply objective
discoverymetrics. To date, it has been challenging to quan-
tify and compare reported discovery rates across different
contexts (e.g., clinical service versus research). Because of
its perceived simplicity, one discovery metric that has
been suggested is the ‘‘solve rate,’’ or the proportion of
investigated families in whom a causal variant for a Men-
delian phenotype is identified. This definition is not partic-
ularly useful on its own given that one could, for example,
achieve a high solve rate by sequencing only families
affected by disorders for which the mutated gene was pre-
viously known.
In an attempt to provide clearly defined measures, we
developed three complementary discovery metrics and
applied them to phenotypes studied by the CMGs on the
basis of strict criteria for (1) variant causality, (2) definitions
of novel and known phenotypes, and (3) definitions of
novel and known genes underlying a Mendelian pheno-
type (Table 1; Figure 7). This was necessary because
although multiple guidelines for assessing causality have
previously been proposed,81,82 none have been operation-
alized, much less used for assessing large-scale gene-discov-
ery efforts studying thousands of families and samples
across hundreds of rare Mendelian phenotypes.
The overall diagnostic rate, defined as the proportion
of families in whom a causal variant was identified, was
0.31 and 0.40 per conservative and suggestive causality
criteria, respectively. This is comparable to diagnostic rates
achieved by clinicalWES, but neither the diagnostic rate in
the CMGs nor its comparison to diagnostic rates of clinical
service labs is a highly informative metric of success. On
the one hand, families studied by the CMGs are specifically
selected to have phenotypes that are less likely to be ex-
plained by an already known gene, thereby potentially
lowering the CMG diagnostic rate. On the other hand,
the CMGs often have the advantage of studying multiple
individuals in a family and multiple families affected by
the same unexplained phenotype, which is predicted to
improve the diagnostic rate.
To date, 647 and 309 genes by conservative and sugges-
tive causality criteria, respectively, or a total of 956 genes,, 2015
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Figure 5. Overview of Deliverables from
the CMGs
Collectively, the CMGs have worked
with 529 investigators from 36 countries
to collect and sequence 16,226 exomes
and 96 genomes. Analyses of these
data have resulted in 956 discoveries.
These discoveries, as well as tools and
technical methods developed by the
CMGs, have led to the publication of 146
manuscripts.were discovered by the CMGs to be implicated in a Mende-
lian phenotype (Table 2). Of the genes discovered by
conservative criteria, 327 were (1) a gene that was not pre-
viously known to underlie a Mendelian phenotype (i.e.,
novel gene) but was found to be implicated in a known
but unexplained phenotype (i.e., a phenotype with an
OMIM number but for which no underlying gene was
known; n ¼ 25) or a novel phenotype (i.e., without an
OMIM number; n ¼ 107); (2) a gene that was previously
known to underlie a Mendelian phenotype (i.e., known
gene) and explained either a different known (n ¼ 4) or a
novel (n¼ 17) phenotype; or (3) a gene that was previously
implicated in aMendelian phenotype and was now discov-
ered to be associated with an expanded set of clinical fea-
tures (i.e., phenotypic expansion, n ¼ 174).
Of our gene discoveries, 320 involved identification of a
known gene that explained a known phenotype; the vast
majority of these phenotypes (e.g., non-syndromic hear-
ing loss [MIM: PS220290, PS124900]), asphyxiating
thoracic dysplasia (MIM: PS208500), and oculocutaneous
albinism (MIM: PS203100) had high locus heterogeneity.
Less commonly, clinical screening failed to identify a
causal variant that was discovered by WES, or a family
was recognized in retrospect to be affected by an explained,
known Mendelian phenotype with a clinical presentation
that was unusual but not different enough to be classified
as a phenotypic expansion. Overall, the causal-gene-iden-
tification rate, defined as the ratio of causal genes identified
to Mendelian phenotypes studied, was 0.51 genes identi-
fied per Mendelian phenotype studied.
If gene discoveries meeting conservative and suggestive
criteria are combined, 617 were (1) a novel gene that was
found to underlie a known, unexplained MendelianThe American Journal of Human Gphenotype (n¼ 52) or a novel pheno-
type (n ¼ 339); (2) a known gene that
explained a different known Mende-
lian phenotype (n ¼ 4) or a novel
Mendelian phenotype (n ¼ 24); or
(3) a gene underlying a phenotypic
expansion (n ¼ 198) (Figure 8). 339
discoveries were for a gene previously
known to underlie the Mendelian
phenotype studied. Accordingly,
the causal-gene-identification rate
combining conservative and sugges-tive criteria was 0.76 genes per Mendelian phenotype
studied.
Analysis of gene-identification rates by mode of inheri-
tance used for modeling segregation in the analysis of
eachphenotype provides further resolution about the types
of Mendelian phenotypes for which gene discovery was
successful and the challenges that remain. Gene-identif-
ication rates based on conservative criteria ranged from
0.29 (multiple models) to 0.66 (autosomal recessive)
(Figure 9A); for comparison, if a causal gene were identified
for everyphenotype, this ratiowould approach amaximum
value of 1. Gene discoveries in consanguineous families
were sometimes complicated by locus heterogeneity and
by the rarity of the phenotype, consistent with a lower-
than-anticipated gene-identification rate (0.60).83,84 Lastly,
the novel-discovery rate, or the proportion of Mendelian
phenotypes in which the gene was newly discovered to
underlie a novel or unexplained phenotype, including
phenotype expansions, was 0.52 (Figures 9B and 9C).
Thus, the novel-discovery rate based on conservative and
suggestive causality criteria was 0.66.
The criteria that we used to estimate novel-discovery
rates were conservative, in large part because causal vari-
ants in the same gene had to be identified in two or
more families affected by the same Mendelian phenotype
or, if a putatively causal variant was found in only one fam-
ily, because both high-confidence mapping and compel-
ling functional data (e.g., recapitulation of the phenotype
in an animal model) were required.81 Given that many of
the Mendelian phenotypes studied are quite rare and
that additional families were not available for study, the
net effect of imposing conservative causality criteria
was a 1.5-fold reduction in the number of Mendelianenetics 97, 199–215, August 6, 2015 205
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Figure 6. Worldwide Interactions with the CMGs
In collaboration with 529 investigators representing 261 institutions in 36 countries (or 1 of every 5 countries [orange] in the world), the
CMGs have collected 18,863 samples from 8,838 families. Approximately 60% (n ¼ 20) of these countries are located outside of North
America, Europe, or Australia.phenotypes we considered unequivocally explained. Yet,
as more families are studied and more data are shared
among researchers and clinicians, our results based on sug-
gestive causality criteria are also likely to lead to genuine
gene discoveries for Mendelian phenotypes.
Lessons Learned and Challenges
The overall rate of discovery made by the CMGs over the
past 3 years has been approximately three discoveries per
week, including the identification of Mendelian pheno-
types associated with 375 genes (128 by conservative
criteria) not previously known to influence human health.
This rate shows no signs of decreasing. Discovery at this
scale has also provided guidance about the most effective
analytical strategies for gene discovery and, in conjunction
with the efforts of other research groups, has exposed ge-
netic mechanisms of disease (e.g., de novo mutation,
CNVs, digenic inheritance, somatic mosaicism, and vari-
ants that are in the same gene but cause both dominant
and recessive conditions) that are more common than pre-
viously appreciated. For example, de novo mutations were
found to be responsible for a wide range of multiple-
malformation syndromes, including visceral myopathy85
(MIM: 155310), acromelic frontonasal dysostosis86 (MIM:
603671), and Gordon syndrome87 (MIM: 114300), as
well as isolated congenital heart defects88,89 and diaphrag-
matic hernia.90 Facioscapulohumeral muscular dystrophy
2 (MIM: 158901) segregates as a Mendelian condition but
was found to result from digenic inheritance of a D4Z4 mi-
crosatellite repeat on a chromosome 4 haplotype permis-
sive for expression of the embedded gene, double homeo-206 The American Journal of Human Genetics 97, 199–215, August 6box 4 (DUX4 [MIM: 606009]), and a variant in structural
maintenance of chromosomes flexible hinge domain con-
taining 1 (SMCHD1 [MIM: 614982]).91 Mutations in mab-
21-like 2 (C. elegans) (MAB21L2 [MIM: 604357]) underlie
a spectrum of major eye malformations that segregate as
either a dominant or recessive trait.92 Similarly, mutations
in sodium leak channel, nonselective (NALCN [MIM:
611549]), a gene whose mutations are known to cause
an autosomal-recessive condition—infantile hypotonia
with psychomotor retardation and characteristic facies93
(MIM: 615419)—were found to also cause a novel auto-
somal-dominant disorder, CLIFAHDD (congenital contrac-
tures of the limbs and face, hypotonia, and global develop-
mental delay) syndrome.94
When multiple modes of inheritance are consistent
with the segregation pattern observed in a pedigree or
there is otherwise uncertainty about the correct mode of
inheritance for a phenotype (i.e., requiring that each
model be tested separately), it is clear that the rate of
gene discovery is considerably lower than when the
mode of inheritance is known or easily predicted (Figures
9A and 9C). The application of multiple models was often
required because there were too few families for establish-
ing segregation patterns definitively, too little information
for establishing the affectation status of an individual or
stratifying persons by phenotypic similarity, or a combina-
tion thereof. This underscores the need for ascertainment
and deep phenotyping of families along with an infra-
structure for warehousing and sharing exome and
genome data from ‘‘mutation-negative’’ research subjects
and clinical cases. Otherwise, the rate of successful gene, 2015
Table 1. Definitions of Terms Used to Characterize Discovery Type
Term Definition
Phenotype the collection of observable or measurable traits of an individual
Known phenotype a Mendelian phenotype with a MIM number
Explained, known phenotype a Mendelian phenotype with a MIM number and for which a causal variant(s) in one or more genes
is known
Unexplained, known phenotype a Mendelian phenotype with a MIM number and for which no causal variant(s) has been
reported
New phenotype a Mendelian phenotype without a MIM number (MIM number assigned thereafter)
Known gene a gene in which a causal variant(s) has been previously associated with a Mendelian phenotype
Novel gene a gene in which a causal variant(s) has not been previously associated with a Mendelian phenotype
Known gene; explained, known
phenotype
a Mendelian phenotype with a MIM number and for which a causal variant was found in a gene
previously associated with the same phenotype
Novel gene; unexplained, known
phenotype
a Mendelian phenotype with a MIM number, for which no causal variant(s) has been reported,
and for which a causal variant was discovered in novel gene
Novel gene; new phenotype a Mendelian phenotype without a MIM number and for which a causal variant(s) was found
in a gene in which a causal variant(s) has not been previously associated with a Mendelian
phenotype (MIM number assigned thereafter)
Known gene; unexplained, known
phenotype
a Mendelian phenotype with a MIM number, for which a causal variant(s) has not been reported,
and for which a causal variant was found in a gene previously associated with a different phenotype
Known gene; new phenotype a Mendelian phenotype without a MIM number and for which a causal variant was found in a gene
previously associated with a different phenotype (MIM number assigned thereafter)
Phenotype expansion expansion of the spectrum of clinical characteristics of an explained, known Mendelian phenotypeidentification did not differ markedly across different in-
heritance models.
Our results onnovel-discovery rates show thatMendelian
phenotypes caused at least in part by de novomutations are
a rich source of novel discoveries. Additionally, because
several affected persons with de novo mutations in the
same gene can frequently be identified, it is often easier to
satisfy conservative causality criteria in these circumstances
than in rare recessive conditions. Correspondingly, our re-
sults indicate that the rate of novel discovery forMendelian
phenotypes was unexpectedly83 more modest in consan-
guineous familieswhen it was based on an autosomal-reces-
sivemodel and conservative causality criteria. However, the
rate of novel discovery in consanguineous families varied
among centers. The majority of consanguineous families
in the CMG dataset are from geographic regions and popu-
lations poorly represented in public variant databases, and
the ability to deeply phenotype affected individuals is often
limited, both of which reduce the effectiveness of excluding
non-causal variants.84 Additionally, many of the pheno-
types assessed under this model in the CMG dataset (e.g.,
non-syndromic hearing loss, nephrotic syndrome, brain
malformations, or intellectual disability) were categorical
phenotypes with high locus heterogeneity, which we have
demonstrated is associated with lower clinical diagnostic
rates (Figure 1). Accordingly, of the 214 discoveries meeting
conservative criteria andmadeon thebasis of an autosomal-
recessive model, 129 (60%) involved a known gene for an
explained, known phenotype, and only 85 (40%) qualified
as novel discoveries (Figure 9C).The AmerPhenotypic expansions and known genes associated
with a known, unexplained phenotype or a novel pheno-
type composed a substantial fraction of CMG discoveries.
Until recently, the prevailing method by which new Men-
delian phenotypes were described relied on circular logic
restricted to the features of the first clinical report. This
strategy of ascertaining persons with highly similar
phenotypes and subsequent gene discovery within the as-
certained group biases against uncovering mutations that
are in the same gene and that result in new or different
sets of phenotypic features. This phenomenon is apparent
in the CMG discoveries and is most likely far more com-
mon than generally appreciated. In an analysis of data
from OMIM (February 2015), 706 genes or ~24% of all
genes associated with a Mendelian phenotype are respon-
sible for at least two ‘‘clinically discrete’’ phenotypes.
No gene with causal variants could be identified (i.e.,
either no compelling candidate variants could be identi-
fied, or the number of candidate variants remained large)
for approximately half of Mendelian phenotypes assessed
by the CMGs. Failure to identify a gene underlying these
phenotypes is most likely explained by a combination of
biological, technical, and analytical factors.95 WES cannot
detect or has a hard time detecting many types of variants
(e.g., indels, non-coding variants, CNVs, repeat expan-
sions, SVs such as inversions and translocations, etc.).
WGS is better at detecting these variants and will be
increasingly utilized as the cost of this technology is
reduced. In ongoing pilot testing, the CMGs conducted
WGS on ~100 samples selected for a variety of reasons,ican Journal of Human Genetics 97, 199–215, August 6, 2015 207
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Figure 7. Criteria for Establishing Cau-
sality of Discoveries
Flow diagram of decisions and criteria used
for establishing whether gene discoveries
by CMGs (Table 2) were considered causal
by conservative or suggestive guidelines.including insufficient DNA quantity for WES, suspicion
that the causal variant would be unlikely to be detected
by WES, or failure to identify a plausible candidate gene
by prior WES. To date, this pilot testing has not led to a dis-
covery that could not be detected or interpreted byWES or
genotyping arrays (e.g., for CNVs). We anticipate that this
will change as more Mendelian phenotypes fail discovery
efforts using WES and are re-examined by WGS. However
the lack of WGS discoveries in our limited pilot is consis-
tent with a recent study that found that only ~15% of
causal variants identified by clinical WGS would most
likely have been missed by WES. Moreover, although sig-
nificant, this percentage is not high enough to justify the
current additional costs of using WGS on a large scale for
gene discovery, especially because the same study found
that WGS applied to dominantly inherited disorders usu-
ally identified a large number of candidate variants for
which pathogenicity could not be determined.96 As a
result, increasing the use of WGS will require expanded
informatics infrastructure and greatly improved tools and
methods for establishing causality at scale among
the consequentially inflated catalog of candidate vari-
ants (e.g., synonymous variants, non-coding variants,
SVs, etc.).81,97,98
Impact of CMGs Accomplishments on Clinical Care
and the Scientific Community
The translation and impact of the CMGs’ efforts on clin-
ical care has been immediate and substantial.99 Approxi-
mately 521 novel Mendelian phenotypes have been
delineated, and the clinical features of 219 known Mende-
lian phenotypes have been expanded. The net effect of
these advances will be a better understanding of the
genetic and allelic architecture of Mendelian phenotypes,208 The American Journal of Human Genetics 97, 199–215, August 6, 2015an ability to distinguish among
similar phenotypes, and improved
ability to facilitate molecular diag-
nosis for disease. These results are
already having substantial clinical
implications. For example, variants
in genes identified as underlying
Mendelian phenotypes since 2011
by the CMGs and other members of
the Mendelian genetics community
represent ~30% of positive findings
from clinical WES.36 This result em-
phasizes the ongoing importance of
discovering genes underlying disease.
Moreover, CMG discoveries haveadded several hundred putative starting points for the
development of targeted therapeutics for Mendelian
phenotypes.
In aggregate, CMG-facilitated resources and discoveries
have resulted in 146 publications over the past 2.5 years
(Table S3). The discordance between the number of
discoveries made and the number of publications to
date reflects, in part, the time required after gene
discovery for identifying and testing additional families
and elucidating the underlying molecular, developmental,
and physiological mechanisms of disease. These efforts
are undertaken foremost to ensure the validity of the
discovery but also to increase the likelihood of publica-
tion in a high-impact journal.81,82 Accordingly, most
of the discoveries made by the CMGs have yet to be
reported because they were made recently, and additional
experimentation is underway. Nevertheless, this delay
is of considerable concern given the value of gene
discovery as a stimulus for basic research and improved
clinical care. Alternative methods of rapidly reporting
gene discoveries (e.g., online reporting in centralized
databases, rapid communication in print journals, etc.)
have been proposed100,101 but face barriers to imple-
mentation, including the cost of developing and main-
taining an online discovery warehouse, a lack of
consensus as to how to safeguard investigator attribution
and provide credit for academic advancement, and the
benefits investigators perceive to keeping such informa-
tion privileged.
Beyond discovering genes implicated in disease, the
CMGs have developed and disseminated both methods
and tools to (1) enable large-scale inventory and indexing
of Mendelian phenotypes, as well as provide an analysis
module that enables rapid and flexible filtering of WES
Table 2. Summary of Discoveries of Genes Underlying Mendelian Phenotypes
Discovery Type
Evidence of Causality
Conservative Suggestive Total
Known known gene; explained, known phenotype 320 19 339
Novel phenotype expansion 174 24 198
known gene; unexplained, known
phenotype
4 0 4
known gene; new phenotype 17 7 24
novel gene; unexplained, known phenotype 25 27 52
novel gene; new phenotype 107 232 339
Total novel 327 290 617
Total number of discoveries 647 309 956and WGS data coupled with the family or cohort
phenotype data (PhenoDB),80,102(2) facilitate candidate-
gene comparisons among investigators (GeneMatcher),80
(3) reconstruct extended pedigree relationships from
genotype data (PRIMUS [Pedigree Reconstruction and
Identification of a Maximally Unrelated Set]),103 (4)
perform quality control of variant data (VAT),104 and
(5) make computational predictions of the impact of
sequence variants, including non-coding regions (ALOFT
[Annotation of Loss-of-Function Transcripts], CADD
[Combined Annotation-Dependent Depletion],98 and
FunSeq105) (Figure 5).1,049 new phenotypes and unexplained-known phenotypes
have entered the CMG pipeline
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Achieving NHGRI’s goal of understanding the genetic basis
of inherited disease will ultimately require discovering the
gene underlying virtually every Mendelian phenotype.
This achievement will be a cornerstone of precision medi-
cine.67 Today, and for the foreseeable future, the vast ma-
jority of genetic diagnostic tests, primary and incidental
results returned to families, and results that guide clinical
management in children and adults are based on discov-
eries of genes underlying Mendelian phenotypes. The
rapidly growing catalog of phenotypes and causative vari-
ants for Mendelian phenotypes immediately (1) makes itNote
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Figure 8. Breakdown of Discoveries
Made in the 1,049 Mendelian Phenotypes
Assessed in the CMG Pipeline
Phenotypes entering the CMG pipelines
are putatively either new phenotypes or
unexplained, known phenotypes. A sub-
stantial fraction (i.e., 32%) of phenotypes
were found to have causal variants in
known genes, consistent with explained,
known phenotypes. However, a larger frac-
tion (40%) of phenotypes assessed resulted
in discoveries of novel genes in addition to
the expansion of 198 Mendelian pheno-
types. For ~28% of phenotypes assessed,
no causal variant has yet been discovered.
Novel genes are those that were not associ-
ated with anyMendelian phenotype when
a project was accepted by the CMGs. Phe-
notypes are defined on a gene- and/or ge-
notype-centric basis—if a novel gene was
discovered for a known, explained pheno-
type, the phenotype was reclassified as
a novel phenotype because it is almost
certain that deeper phenotyping would
reveal (molecular, biochemical, or physio-
logical) differences that distinguish the
novel phenotype from the previously
known, explained phenotype caused by
mutations in another gene.
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Figure 9. Discovery Metrics under
Different Models of Inheritance for Men-
delian Phenotypes Studied by the CMGs
(A) The percentage of Mendelian pheno-
types for which a gene was discovered on
the basis of conservative causality criteria
per different models of inheritance with
mapping data (dark green) or without
mapping data (light green) is shown. Also
shown is the percentage ofMendelian phe-
notypes for which a causal gene was not
found per different models of inheritance
with mapping data (dark gray) or without
mapping data (light gray). Note that for
most phenotypes analyzed under an auto-
somal-recessive homozygous model that
failed, mapping data were available; how-
ever, the statistical significance of the map-
ping data varied (e.g., number and length
of runs of homozygosity, magnitude of
LOD score, etc.). The mean number of
genes discovered per Mendelian pheno-
type was 0.52 or 0.76 on the basis of only
conservative or combined conservative
and suggestive criteria, respectively. These
figures do not include results from persons
found to have more than one Mendelian
phenotype.
(B) Classification of discoveries of genes
underlying Mendelian phenotypes as
known (white squares) or novel (blue
squares).
(C) Percentage of Mendelian phenotypes
for which a novel discovery (dark blue)
or known discovery (light blue) was made
on the basis of conservative causality
criteria per differentmodels of inheritance.
The mean number of novel discoveries per
Mendelian phenotype was 0.52 or 0.66
on the basis of only conservative or com-
bined conservative and suggestive criteria,
respectively.
Abbreviations are as follows: AD, auto-
somal dominant; AR, autosomal recessive
(when recessive inheritance was clear, but
analysis of both consanguineous and
non-consanguineous families contributed
to the discovery); AR homozygous, auto-
somal recessive in a consanguineous fam-
ily; AR heterozygous, autosomal recessive
in a non-consanguineous family (i.e., com-
pound-heterozygous mutations).possible for clinical laboratories to rapidly improve rates of
molecular diagnosis for rare diseases, (2) advances the
development and re-purposing of therapeutics, and (3) em-
powers clinicians to improve the care and management of
individuals with a very wide spectrum of conditions.
Accordingly, discovering the cause of most, if not all, Men-
delian phenotypes could transform the practice of medi-
cine and the care of families.
Of broader interest to the biomedical research commu-
nity, discovery of genes implicated in all Mendelian phe-
notypes will (1) connect genes and their protein products
to biological systems and clinical phenotypes, (2) provide
a pathway for developing better strategies to find genetic
and environmental modifiers underlying common dis-210 The American Journal of Human Genetics 97, 199–215, August 6eases, and (3) enable understanding of the functional
and phenotypic consequences of non-coding variation.
Indeed, it is becoming increasingly clear that, in the
absence of deep phenotypic characterization, genomic in-
formation even from a large number of individuals is of
limited value. Moreover, what can be understood about
gene function and phenotypic consequences is propor-
tional to the breadth and diversity of conditions studied.
To this end, our results and experiences suggest that the
full power of human genomics to explain fundamental
biological processes and rapidly transform medical care
might be more readily realized by discovery of the genetic
basis of all Mendelian phenotypes rather than large-scale
sequencing of a handful of common diseases., 2015
During the next 5 years, there will be a growing need for
(1) keystone projects (e.g., to delineate and deeply pheno-
type all Mendelian phenotypes, to catalog all validated
large-effect variants underlying Mendelian phenotypes,
etc.) to empower the biomedical community and (2)
large-scale projects to explain the functional consequences
of variants responsible for all Mendelian phenotypes.
These projects will generate a complete catalog of the
phenotypic characteristics for all Mendelian disorders
and the relationships that distinguish them; identify, in-
dex, and warehouse all causal variants linked to all Mende-
lian phenotypes and the range of different phenotypic
features observed within each individual Mendelian disor-
der; and pioneer new approaches and analytical methods
that can be exploited at scale for the discovery of genes un-
derlying Mendelian phenotypes and rare disorders caused
by non-traditional modes of inheritance (e.g., oligogenic,
de novo, somatic mosaicism, uniparental disomy, etc.)
and for explaining their overall contribution to the burden
of human disease.Supplemental Data
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